FDA reviewing RSV vaccines studied by URMC
ROCHESTER, N.Y. The FDA is currently reviewing candidates for two RSV vaccines and the University of Rochester Medical Center is helping lead the charge.
The medical center says it studied three of the four RSV vaccines currently in development. The virus has become an increasing concern with 60,000 to 120,000 people being hospitalized each year.
URMC is hoping for the FDA to approve the vaccine by summer or early fall.